Catalog Products » FCRL2/IRTA4, His, Human
Manual
Manual
COAs

FCRL2/IRTA4, His, Human

Fc receptor-like 2 (FCRL2) is highly expressed on B-cell chronic lymphocytic leukemia (B-CLL) cells and could possibly influence disease pathogenesis. FCRL2 mRNA expression was found to be expressed at considerably higher levels in peripheral blood mononuclear cells (PBMC) of B-CLL patients compared to controls (range 1.35- to 210-fold upregulation; P < 0.0001) and cells of other hematological diseases.
$410.00
Z05284-100

Ask us a question
Product Introduction
Species Human
Protein Construction
FCRL2/IRTA4 (Leu20-Val401)
Accession # Q96LA5-1		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 42.7 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 60-70 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

FCRL2/IRTA4, His, Human

Immobilized FCRL2/IRTA4, His, Human, His Tag at 5 μg /ml (100 μl/well) on the plate. Dose response curve for Anti-FCRL2 Antibody, hFc Tag with the EC50 of 51.3ng/ml determined by ELISA. »

FCRL2/IRTA4, His, Human

The purity of FCRL2/IRTA4, His, Human is greater than 95% as determined by SEC-HPLC. »

FCRL2/IRTA4, His, Human

FCRL2/IRTA4, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

Background
Target Background Fc receptor-like 2 (FCRL2) is highly expressed on B-cell chronic lymphocytic leukemia (B-CLL) cells and could possibly influence disease pathogenesis. FCRL2 mRNA expression was found to be expressed at considerably higher levels in peripheral blood mononuclear cells (PBMC) of B-CLL patients compared to controls (range 1.35- to 210-fold upregulation; P < 0.0001) and cells of other hematological diseases.
Synonyms FcR-like protein 2; FcRL2; FCRH2; IFGP4; IRTA4; FCRL2; CD307b; FCRH2SPAP1B; IRTA4SPAP1C; SPAP1; SPAP1A
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.